Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
about
Dissecting the host response to a gamma-herpesvirus.Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesDNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.A commonly recognized simian immunodeficiency virus Nef epitope presented to cytotoxic T lymphocytes of Indian-origin rhesus monkeys by the prevalent major histocompatibility complex class I allele Mamu-A*02.Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccinationA human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primatesLong-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques.Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesSubsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo.Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Strategies for an HIV vaccine.Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeysVaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferonEffect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.Cytotoxic T lymphocytes in protection against equine infectious anemia virus.The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responsesHIV vaccine design: insights from live attenuated SIV vaccines.Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesMultigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeProgress and obstacles in the development of an AIDS vaccine.With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope.Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.The Mamu B 17-restricted SIV Nef IW9 to TW9 mutation abrogates correct epitope processing and presentation without loss of replicative fitness.Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challengeNef-mediated MHC class I down-regulation unmasks clonal differences in virus suppression by SIV-specific CD8(+) T cells independent of IFN-gamma and CD107a responsesRecombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responsesPrime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infectionVaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.
P2860
Q33772250-53F84F7B-C15E-4888-8D7B-AC94706DD162Q33780685-84ABBC44-8E17-4383-9DF0-B6E3C7E3D11BQ33843297-0F633C7F-6795-438E-8B3C-803A855D2917Q33847656-C652B6EF-6EBD-48FE-99F6-904198A11041Q33851802-670CBD91-A99B-416A-82B1-80D62B6068FEQ33883854-95FA3FF9-48A1-4734-AB94-8C35C7912631Q34099837-10A89D48-E77D-4CEA-93B2-A9C88CE55E26Q34227778-99F8CD2F-184E-4F77-9CF6-840F7D1B34E2Q34228507-D8FCCA84-1456-4B1E-8B29-A4D397806A4DQ34250318-E63B1BF6-19EC-4970-BC6C-CC872078E838Q34255654-E7E11F0F-AB5A-42A5-94FA-44FC26422565Q34326532-E9AC4B2B-CD8F-40E0-9346-D00D867CF812Q34348640-C50C821E-A85B-4827-A408-B172A7732AB8Q34362699-E6192379-4FE3-4DEF-8DA7-2D2ACE6681A0Q34428561-EE92A45F-DCDB-4E6D-8C67-3220543A2DDDQ34462167-2E405551-7605-462C-BBC7-58DBA524C25AQ34554756-A6DA3737-CB69-4EF0-8756-BBC028B92C13Q34651604-9476E23F-43C7-46E8-96A5-D3319218E228Q34717847-D9ED1BD4-0842-45EC-8278-62C5EE9223E6Q35149425-61F10D43-B82F-4EFD-96EF-8FCC4BAEEC07Q35634943-478DFF78-7EF9-45E7-8B14-265803600613Q35857581-4B9BCA91-8C5E-402B-B206-24883EECD282Q36177395-E0A9E1B4-07B3-43CC-A63C-EF014F8C3E1FQ36256348-849AD013-27F0-4C62-9DDD-7C11BE42CB74Q36343536-35AD3EC9-BAE1-496C-B4C8-5673E3E5C96CQ36402663-F5804BD1-7156-43B7-B54F-7B0740C731C2Q36424574-FB735646-8A4C-4EAE-A81F-850E355DC8B1Q36538907-93B33583-A25B-48D4-947A-5C7474857DADQ36662462-73D082BF-EA8F-4F70-B326-D5BCB5B60CDBQ36949843-7B8CB704-EFC3-4245-A215-9A12D881C0B5Q36954239-7A47933E-18D3-47AB-8267-677B77D53DBDQ37060336-6BEDE165-3497-4435-82E4-92DF45AB434DQ37171639-23F12559-EB93-450C-A82D-71F15F126667Q37198515-D82C89D5-F947-4553-97F5-4E9980AE5B1EQ37232824-256B6E17-FB3C-4484-A78F-397B98415C6AQ37276902-E935341B-C4F3-4AB5-A609-2D1D935FD0FCQ37285535-7A9A0B48-A3A2-4A97-8489-3B211207BFB7Q37355979-C9F50D0A-7D04-4BA6-9065-E74A9CFB14C9Q37492847-6EFAA35E-067C-41E4-A182-91FDE3FB6EE4Q37530461-D027F3FB-DEC2-49FB-95E7-5FD2DBB2B16A
P2860
Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@ast
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@en
type
label
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@ast
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@en
prefLabel
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@ast
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@en
P2093
P2860
P1433
P1476
Simian immunodeficiency virus ...... fter pathogenic SIV infection.
@en
P2093
C E Nickerson
J E Schmitz
J W Shiver
K Tenner-Racz
M A Lifton
M J Kuroda
N L Letvin
P2860
P304
P356
10.1128/JVI.74.16.7485-7495.2000
P577
2000-08-01T00:00:00Z